-
BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023
•
BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene (BMS, NYSE: BMY), formally ending their previous partnership on December 31, 2023. As part of the agreement, both parties have agreed to withdraw arbitral proceedings. Bristol-Myers Squibb/Celgene will transfer 23,273,108 ordinary shares of BeiGene back…
-
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s Otezla (apremilast) has obtained marketing approval from the National Medical Products Administration (NMPA), signifying that it has passed the generic quality and efficacy consistency evaluation. Apremilast’s Background and Clinical Necessity in ChinaApremilast, an oral small…
